ARXIS INC (ARXS)

NASDAQIndustrialsAerospace & DefenseSnapshot 2026-10-15

$54.10+0.54%

Close 2026-10-16 · 1-day change

Read the published Living FV report summary

Investment OutlookAs of Oct 15, 2026

What could strengthen or challenge ARXIS INC’s outlook?

The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.

Higher potential upsideImproving expectations

Next-FY EPS estimate change · 30 days

Comparable estimates unavailable

+10% or more+5%0%−5%−10% or less

A matching fiscal period and sufficient coverage are required.

Higher risk of downsideWeakening expectations

One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.

How this is measured

The calculation requires same-period, same-provider snapshots, positive EPS, at least five analysts and a baseline within three days of the requested lookback.

Living FV™

Living Fair Value by QuarterlyIQ

A valuation that evolves as the business changes.

A published Living FV snapshot is not available yet. The valuation workflow remains discoverable; a market target cannot supply the missing evidence.

View Living FV report and workflow

What the Thesis Depends On

Three key conditions need to be met for the investment thesis to play out.

Key Factor	Why It Matters	Current Status	Break Condition	Latest Evidence
Expand product portfolio via strategic acquisitions	A supporting condition in ARXIS INC's published investment case. The stated target is Complete acquisitions that expand key segments.	Intact	No meaningful acquisitions completed or integration fails	2 acquisitions completed vs target of meaningful expansion Multiple large acquisitions completed in 2026, including Omnetics and MagCanica, expanding key segments. Context reviewed through Oct 15, 2026Last status assessment Oct 15, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management context Stated in 3 disclosures including 2026-Q1 and 2026-Q2. Management completed the acquisitions of MagCanica and Omnetics, expanding the portfolio and precision sensing capabilities. The combined purchase price multiple is about 12x FY27 estimated adjusted EBITDA. The trajectory is delivering with completed acquisitions and integration underway. Delivery assessment Oct 15, 2026
Deliver adjusted EBITDA of $720M to $730M in 2026	A primary condition in ARXIS INC's published investment case. The stated target is $720M+.	Intact	EBITDA falls below $720M in 2026	Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Source date unavailableLast status assessment Oct 15, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
Achieve full-year 2026 revenue of $1.86B to $1.88B	A primary condition in ARXIS INC's published investment case. The stated target is ~$1.87B.	Intact	Revenue falls below $1.86B in 2026	Revenue: $500.728M FY2026-Q2; GAAP. Published target: ~$1.87B. Target period is not explicitly aligned with this observation. Source published Jul 30, 2026500,728,000 USD · source valueSource reportLast status assessment Oct 15, 2026 Measurement source consolidated · GAAP FY2026-Q2 · Period ending Jun 30, 2026 Source: company_financial_results. Reference: c2e46741-8ca9-4388-8c6f-3d6f2632cc33. Source status: eligible. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.

Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.

Incoming Evidence

Compare these dated observations with the operating requirements above

Expectations trend

Same fiscal period

FY2027 · fiscal year ending 2027-12-31 · fmp

FY2027 EPSUnavailable

$0.71 → Unavailable · observed estimates

FY2027 revenue$2.37B

$2.08B → $2.37B · observed estimates

Exact estimates & source dates

One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.

FY2027 estimate observations · fmp
Snapshot	EPS	Revenue	EPS / revenue analysts
2026-07-24	$0.71	$2,076,978,568	5 / 7
2026-07-25	$0.93	$2,078,163,380	8 / 10
2026-07-26	$0.93	$2,078,163,380	8 / 10
2026-07-27	$0.71	$2,076,978,570	5 / 7
2026-07-28	$0.93	$2,078,163,380	8 / 10
2026-07-29	$0.93	$2,078,163,380	8 / 10
2026-07-30	$0.93	$2,078,163,380	8 / 10
2026-07-31	$0.93	$2,078,163,380	8 / 10
2026-08-01	$0.93	$2,078,163,380	8 / 10
2026-08-02	$1.15	$2,168,733,100	8 / 10
2026-08-03	$1.15	$2,168,733,100	8 / 10
2026-08-04	$1.15	$2,168,733,100	8 / 10
2026-08-05	$1.21	$2,224,799,090	9 / 11
2026-08-06	$1.21	$2,224,799,090	9 / 11
2026-08-07	$0.78	$2,140,773,349	5 / 7
2026-08-08	$1.22	$2,224,790,530	10 / 11
2026-08-09	$1.22	$2,224,790,530	10 / 11
2026-08-10	$1.22	$2,224,790,530	10 / 11
2026-08-11	$1.22	$2,224,790,530	10 / 11
2026-08-12	$1.22	$2,224,790,530	10 / 11
2026-08-13	$1.22	$2,224,790,530	10 / 11
2026-08-14	$0.78	$2,140,773,349	5 / 7
2026-08-15	$0.78	$2,140,773,349	5 / 7
2026-08-16	$0.78	$2,140,773,349	5 / 7
2026-08-17	$0.78	$2,140,773,349	5 / 7
2026-08-18	$0.78	$2,140,773,349	5 / 7
2026-08-19	$0.78	$2,140,773,349	5 / 7
2026-08-20	$0.87	$2,252,244,466	6 / 8
2026-08-21	$0.87	$2,252,244,466	6 / 8
2026-08-22	$0.87	$2,252,244,466	6 / 8
2026-08-23	$0.87	$2,252,244,466	6 / 8
2026-08-24	$0.87	$2,252,244,466	6 / 8
2026-08-25	$0.87	$2,252,244,466	6 / 8
2026-08-26	$0.87	$2,252,244,466	6 / 8
2026-08-27	$0.87	$2,252,244,466	6 / 8
2026-08-28	$0.87	$2,252,244,466	6 / 8
2026-08-29	$0.87	$2,252,244,466	6 / 8
2026-08-30	$0.87	$2,248,516,757	6 / 8
2026-08-31	$0.87	$2,248,516,757	6 / 8
2026-09-01	$0.87	$2,248,516,757	6 / 8
2026-09-02	$0.87	$2,248,516,757	5 / 7
2026-09-03	$0.87	$2,248,516,757	5 / 7
2026-09-04	$0.87	$2,248,516,757	5 / 7
2026-09-05	$0.89	$2,248,471,739	5 / 7
2026-09-06	$0.89	$2,248,471,739	5 / 7
2026-09-07	$0.89	$2,248,471,739	5 / 7
2026-09-08	$0.92	$2,248,471,739	5 / 7
2026-09-09	$0.92	$2,248,471,739	5 / 7
2026-09-10	$0.92	$2,248,471,739	5 / 7
2026-09-11	$0.92	$2,248,471,737	5 / 7
2026-09-12	$0.92	$2,248,471,737	5 / 7
2026-09-13	$0.92	$2,248,471,737	5 / 7
2026-09-14	$0.92	$2,248,471,737	5 / 7
2026-09-15	$0.92	$2,248,471,737	5 / 7
2026-09-16	$0.92	$2,248,471,737	5 / 7
2026-09-17	$0.92	$2,248,471,737	5 / 7
2026-09-18	$0.92	$2,248,471,737	5 / 7
2026-09-19	$0.92	$2,248,471,737	5 / 7
2026-09-20	$0.92	$2,248,471,737	5 / 7
2026-09-21	$0.92	$2,248,471,737	5 / 7
2026-09-22	$0.92	$2,248,471,737	5 / 7
2026-09-23	$0.92	$2,248,471,737	5 / 7
2026-09-24	$0.92	$2,248,471,737	5 / 7
2026-09-25	$0.92	$2,248,471,737	5 / 7
2026-09-26	$0.92	$2,269,631,828	5 / 7
2026-09-27	$0.92	$2,269,631,828	5 / 7
2026-09-28	$0.92	$2,269,631,828	5 / 7
2026-09-29	$0.92	$2,269,631,828	5 / 7
2026-09-30	$0.92	$2,269,631,828	5 / 7
2026-10-01	$0.92	$2,287,941,965	5 / 7
2026-10-02	Unavailable	Unavailable	3 / 3
2026-10-03	Unavailable	Unavailable	4 / 4
2026-10-04	Unavailable	Unavailable	4 / 4
2026-10-05	Unavailable	Unavailable	4 / 4
2026-10-06	Unavailable	Unavailable	4 / 4
2026-10-07	Unavailable	Unavailable	3 / 4
2026-10-08	Unavailable	Unavailable	3 / 4
2026-10-09	Unavailable	$2,347,760,060	4 / 5
2026-10-10	Unavailable	$2,347,760,060	4 / 5
2026-10-11	Unavailable	$2,347,760,060	4 / 5
2026-10-12	Unavailable	$2,347,760,060	4 / 5
2026-10-13	Unavailable	$2,372,689,333	4 / 6
2026-10-14	Unavailable	$2,372,689,333	4 / 6
2026-10-15	Unavailable	$2,372,689,333	4 / 6

Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.

Compare required revenue and earnings

Analyst view

Monthly observations

Buy / Strong BuyHoldSell / Strong Sell

Exact monthly counts

Monthly rating snapshots · fmp. Missing snapshots are not zero.
Date	Buy*	Hold
2026-05-01	10	1
2026-06-01	10	1
2026-07-01	10	1
2026-08-01	10	1
2026-09-01	10	1
2026-10-01	11	1

*Buy includes Strong Buy; Sell includes Strong Sell. Monthly counts describe the analyst mix, not the firms behind each recent action.

Latest: 11 Buy / Strong Buy · 1 Hold · 0 Sell / Strong Sell

1 upgrades0 downgrades0 maintains

Recent actions · Sep 16–Oct 15 · 1 recorded

Price-target changes

30 days

○ Previous · ● Latest · common dollar scale

RBC CapitalOct 2 · prior May 29

$46.00 → $60.00+30.4%

$0$33.00$66.00

1 raises · 0 cuts · 0 unchanged · 0 without a comparable prior

How this is measured

Sep 16, 2026–Oct 15, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.

Outlook in Brief

The evidence, the remaining questions, and what comes next

What's improving

No recovery evidence is reported in the available driver assessments.

Still unresolved / key risks

Deliver adjusted EBITDA of $720M to $730M in 2026Direct metric needs a verified mapping
Achieve full-year 2026 revenue of $1.86B to $1.88BRevenue: $500.728M

Next proof point

Nov 4, 2026

Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.

Review earnings

Bottom line

2 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.

The dated weekly assessment and its assumptions are available in Read detailed Outlook.

Historical risk context

Observed price history; separate from operating scenarios

Price sensitivity

1.6%Typical daily move · historical

Downside history

-22.0%Maximum drawdown · trailing year

Read detailed Outlook Company context, assumptions & risks

ARXIS INC outlook in detail

The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.

Updated Oct 10, 2026

What kind of bet this is

This investment represents a durable compounder with a focus on growth through strategic acquisitions. The current thesis is intact, supported by recent financial performance and a raised revenue outlook.

What's priced into ARXIS INC

The market appears to be pricing in a low level of fragility, with no significant risks currently affecting the stock. However, ARXS trades at a premium compared to its peers, reflecting expectations for continued growth.

What the fundamentals likely do

Fundamentals are likely to remain stable, with management on track to achieve its revenue and EBITDA targets for 2026. There is a low probability of missing these targets, although recent earnings surprises have been trending down.

What ARXIS INC hinges on

The thesis hinges on the performance of sector bellwethers like SPCX, GE, and RTX. Positive earnings from these companies could bolster ARXS, while negative guidance could pose risks to its growth trajectory.